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Animal experiments have contributed
much to our understanding of mechanisms
of disease, but their value in predicting the
effectiveness of treatment strategies in
clinical trials has remained controversial
[1–3]. In fact, clinical trials are essential
because animal studies do not predict with
sufficient certainty what will happen in
humans. In a review of animal studies
published in seven leading scientific jour-
nals of high impact, about one-third of the
studies translated at the level of human
randomised trials, and one-tenth of the
interventions, were subsequently approved
for use in patients [1]. However, these
were studies of high impact (median
citation count, 889), and less frequently
cited animal research probably has a lower
likelihood of translation to the clinic. De-
pending on one’s perspective, this attrition
rate of 90% may be viewed as either a
failure or as a success, but it serves to
illustrate the magnitude of the difficulties
in translation that beset even findings of
high impact.
Recent examples of therapies that failed
in large randomised clinical trials despite
substantial reported benefit in a range of
animal studies include enteral probiotics
for the prevention of infectious complica-
tions of acute pancreatitis, NXY-059 for
acute ischemic stroke, and a range of
strategies to reduce lethal reperfusion
injury in patients with acute myocardial
infarction [4–7]. In animal models of
acute ischemic stroke, about 500 ‘‘neuro-
protective’’ treatment strategies have been
reported to improve outcome, but only
aspirin and very early intravenous throm-
bolysis with alteplase (recombinant tissue-
plasminogen activator) have proved effec-
tive in patients, despite numerous clinical
trials of other treatment strategies [8,9].
Causes of Failed Translation
The disparity between the results of
animal models and clinical trials may in
part be explained by shortcomings of the
clinical trials. For instance, these may
have had insufficient statistical power to
detect a true benefit of the treatment
under study. For practical or commercial
purposes, the designs of some clinical
trials have also failed to acknowledge the
limitations of efficacy observed in animal
studies, for example by allowing therapy
at later time points when the window of
opportunity has passed [10,11]. Second-
ly, the failure of apparently promising
interventions to translate to the clinic
may also be caused by inadequate ani-
mal data and overoptimistic conclusions
about efficacy drawn from methodologi-
cally flawed animal studies. A third
possible explanation is the lack of exter-
nal validity, or generalisability, of some
animal models; in other words, that these
do not sufficiently reflect disease in
humans. Finally, neutral or negative
animal studies may be more likely to
remain unpublished than neutral clinical
trials, giving the impression that the first
are more often positive than the second.
This article aims to address the possible
sources of bias that threaten the internal
and external validity of animal studies, to
provide solutions to improve the relia-
bility of such studies, and thereby to im-
prove their translation to the clinic.
Internal Validity
Adequate internal validity of an animal
experiment implies that the differences
observed between groups of animals
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Publication bias confounds at-
tempts to use systematic reviews
to assess the efficacy of various
interventions tested in experiments
modeling acute ischemic stroke,
leading to a 30% overstatement of
efficacy of interventions tested in
animals.
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allocated to different interventions may,
apart from random error, be attributed to
the treatment under investigation [12].
The internal validity may be reduced by
four types of bias through which system-
atic differences between treatment groups
are introduced (Table 1). Just like any
clinical trial, each formal animal study
testing the effectiveness of an intervention
should be based on a well-designed study
protocol addressing the design and con-
duct of the study, as well as the analysis
and reporting of its results. Aspects of the
design, conduct, and analysis of an animal
experiment that help to reduce bias and to
improve the reliability and reproducibility
of the results are discussed below. As the
impact of study quality has been studied
much more extensively in clinical trials
than in animal studies, the backgrounds
and recommendations regarding these
issues are largely based on the clinical
CONsolidated Standards of Reporting
Trials (CONSORT) statement, and to a
smaller extent on published recommenda-
tions and guidelines for the conduct and
reporting of animal studies of acute
ischemic stroke [13–17].
Randomisation
To prevent selection bias, treatment
allocation should be based on randomisa-
tion (Box 1), a method that is almost
ubiquitous in clinical treatment trials. In
part, this prevents the investigator from
having to choose which treatment a
particular animal will receive, a process
which might result (consciously or subcon-
sciously) in animals which are thought to
do particularly well or particularly badly
being overrepresented in a particular
treatment group. Foreknowledge of treat-
ment group assignment may also lead to
selective exclusion of animals based on
prognostic factors [13]. These problems
can arise with any method in which group
allocation is known in advance or can be
predicted. Such methods include both the
use of predetermined rules (e.g., assign-
ment in alternation or on the basis of the
days of the week) or of open randomisation
schedules. Picking animals ‘‘at random’’
from their cages also has the risk of
conscious or subconscious manipulation,
and does not represent true randomisation.
Randomisation may appear redundant
if the animals form a homogeneous group
from a genetic and environmental per-
spective, as often is the case with rats and
other rodents. However, it is not only the
animal itself but mainly the induction of
the disease that may give rise to variation.
For example, there is a large variation in
infarct size in most rat models of ischaemic
stroke not only because of interindividual
differences in collateral circulation—even
in inbred strains—but also because in
some animals the artery is occluded better
than in others and because the models are
inherently vulnerable to complications
that may affect outcome, such as peripro-
cedural hypotension or hypoxemia. It is
because of this variation that randomisa-
tion, ideally occurring after the injury or
disease has been induced, is essential.
In clinical trials, automated randomisa-
tion techniques such as random number
generation are most commonly used, but
manual methods (such as tossing a coin or
throwing dice) are also acceptable as long
as these cannot be manipulated. By
preference, such manual techniques
should be performed by an independent
person.
Blinding
In studies that are blinded throughout
their course, the investigators and other
persons involved will not be influenced by
knowledge of the treatment assignment,
thereby preventing performance, detec-
tion, and attrition bias. Knowledge of
treatment assignment may subconsciously
or otherwise affect the supply of additional
care, outcome assessment, and decisions to
withdraw animals from the experiment.
In contrast to allocation concealment
(Box 1), blinding may not always be
possible in all stages of an experiment,
for example when the treatment under
investigation concerns a surgical proce-
Summary Points
N The value of animal experiments for predicting the effectiveness of treatment
strategies in clinical trials has remained controversial, mainly because of a
recurrent failure of interventions apparently promising in animal models to
translate to the clinic.
N Translational failure may be explained in part by methodological flaws in animal
studies, leading to systematic bias and thereby to inadequate data and
incorrect conclusions about efficacy.
N Failures also result because of critical disparities, usually disease specific,
between the animal models and the clinical trials testing the treatment
strategy.
N Systematic review and meta-analysis of animal studies may aid in the selection
of the most promising treatment strategies for clinical trials.
N Publication bias may account for one-third or more of the efficacy reported in
systematic reviews of animal stroke studies, and probably also plays a
substantial role in the experimental literature for other diseases.
N We provide recommendations for the reporting of aspects of study quality in
publications of comparisons of treatment strategies in animal models of
disease.
Table 1. Four types of bias threatening internal validity.
Type of Bias Definition Solution
Selection bias Biased allocation to treatment groups Randomisation; allocation concealment
Performance bias Systematic differences in care between the treatment groups,
apart from the intervention under study
Blinding
Detection (ascertainment, assessment, or
observer) bias
Systematic distortion of the results of a study that occurs when the
person assessing outcome has knowledge of treatment assignment.
Blinding
Attrition bias Unequal occurrence and handling of deviations from protocol
and loss to follow-up between treatment groups
Blinding; intention-to-treat analysis
Adapted from [12,13].
doi:10.1371/journal.pmed.1000245.t001
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dure. However, blinding of outcome as-
sessment is almost always possible.
In clinical trials, the most common form
of blinding is double blinding, in which the
patients, the investigators, and the care-
givers are unaware of the intervention
assignment. Because the patient does not
know which treatment is being adminis-
tered, the placebo effect will be similar
across the comparison groups. As animals
are not susceptible to the placebo effect,
double blinding is not an issue in animal
studies. Notwithstanding the influence that
unblinded animal handling can have on
performance in neurobehavioural tasks
[18], the fact that in some articles of
animal studies ‘‘double blinding’’ is re-
ported raises questions about the authors’
knowledge of blinding as well as about the
review and editorial processes of the
journals in which the studies were pub-
lished [19,20].
Sample Size Calculation
Selection of target sample size is a critical
factor in the design of any comparison
study. The study should be large enough to
have a high probability of detecting a
treatment effect of a given size if such an
effect truly exists, but also pay attention to
legal requirements and ethical and practical
considerations to keep the number of
animals as small as possible. The required
sample size should be determined before
the start of the study with a formal sample
size calculation, of which the fundamental
elements of statistical significance (a), effect
size (d), power (1–b), and standard devia-
tion of the measurements have been ex-
plained in numerous articles [13,21]. Un-
fortunately, the assumptions on variation of
the measurements are often based on
incomplete data, and small errors can
lead to a study that is either under- or
overpowered. From an ethical point of
view, underpowered studies are undesir-
able, as they might lead to the false
conclusion that the intervention is without
efficacy, and all included animals will have
been used to no benefit. Overpowered
studies would also be unethical, but these
are much less prevalent.
Monitoring of Physiological
Parameters
Depending on the disease under inves-
tigation, a range of physiological variables
may affect outcome, and inadequate
control of these factors may lead to
erroneous conclusions. Whether or not
physiological parameters should be assess-
ed, and for how long, therefore depends
on the model and on the tested condition.
Eligibility Criteria and Drop-Outs
Because of their complexity, many
animal models are inherently vulnerable
to complications—such as inadvertent
blood loss during surgery to induce
cerebral or myocardial ischemia—that
are not related to the treatment under
study but that may have a large effect on
outcome. Given the explanatory character
of preclinical studies, it is justifiable to
exclude animals with such complications
from the analyses of treatment effects,
provided that the eligibility criteria are
predefined and not determined on a post-
hoc basis, and that the person responsible
for the exclusion of animals is unaware of
the treatment assignment.
In clinical trials, inclusion and exclusion
criteria are usually applied before enrol-
ment in the study, but for the reason
above, in animal studies it is justifiable also
to apply these criteria during the course of
the study. However, these should be
limited to complications that are demon-
strably not related to the intervention
under study, as this may otherwise lead
to attrition bias. For example, if a potential
novel treatment for colorectal cancer
increases instead of reduces tumour pro-
gression, thereby weakening the animals
and increasing their susceptibility to infec-
tions, exclusion of animals dying prema-
turely because of respiratory tract infec-
tions may lead to selective exclusion of
animals with the largest tumours and
mask the detrimental effect of the novel
intervention.
Statistical Analysis
The statistical analysis of the results of
animal experiments has been given elab-
orate attention in review articles and books
[22]. However, even when data appear
simple and their analysis straightforward,
inadequate techniques are often used.
Common examples include the use of a
t-test for nonparametric data, calculating
means and standard deviations for ordinal
data, and treating multiple observations
from one animal as independent.
In clinical trials, an intention-to-treat
analysis is generally favoured because it
avoids bias associated with nonrandom
loss of participants [13]. As explained
above, the explanatory character of most
studies justifies the use of an analysis
restricted to data from animals that have
fulfilled all eligibility criteria, provided that
all animals excluded from the analysis are
accounted for and that those exclusions
have been made without knowledge of
treatment group allocation.
Control of Study Conduct
The careers of investigators at academic
institutions and in industry depend in part
on the number and impact of their
publications, and these investigators may
be all too aware of the fact that the
prospect of their work being published
Box 1. Glossary
N Allocation concealment: Concealing the allocation sequence from those
assigning animals to intervention groups, until the moment of assignment.
N Bias: Systematic distortion of the estimated intervention effect away from the
‘‘truth,’’ caused by inadequacies in the design, conduct, or analysis of an
experiment.
N Blinding (masking): Keeping the persons who perform the experiment,
collect data, and assess outcome unaware of the treatment allocation.
N Eligibility criteria: Inclusion and exclusion criteria: the characteristics that
define which animals are eligible to be enrolled in a study.
N External validity: The extent to which the results of an animal experiment
provide a correct basis for generalisations to the human condition.
N Intention-to-treat analysis: Analysis of data of all animals included in the
group to which they were assigned, regardless of whether they completed the
intervention.
N Internal validity: The extent to which the design and conduct of the trial
eliminate the possibility of bias.
N Power: The probability that a study will detect a statistically significant effect of
a specified size.
N Randomisation: Randomly allocating the intervention under study across the
comparison groups, to ensure that group assignment cannot be predicted.
N Sample size: The number of animals in the study
Definitions adapted from [13] and from Wikipedia (http://www.wikipedia.org,
accessed on 9 November 2009).
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increases when positive results are ob-
tained. This underscores not only the
importance of randomisation, allocation
concealment, and blinding, but also the
need for adequate monitoring and audit-
ing of laboratory experiments by third
parties. Indeed, adopting a multicentre
approach to animal studies has been
proposed, as a way of securing transparent
quality control [23].
Bias in Animal Studies
The presence of bias in animal studies
has been tested most extensively in studies
of acute ischemic stroke, probably because
in this field the gap between the laboratory
and the clinic is both very large and well
recognised [8]. In systematic reviews of
different interventions tested in animal
models of acute ischemic stroke, other
emergencies, Parkinson’s disease, multiple
sclerosis, or amyotrophic lateral sclerosis,
generally about a third or less of the
studies reported random allocation to the
treatment group, and even fewer studies
reported concealment of treatment alloca-
tion or blinded outcome assessment
[2,16,19,24,25]. Even when reported, the
methods used for randomisation and
blinding were rarely given. A priori sample
size calculations were reported in 0%–3%
of the studies (Table 2).
Complications of the disease and/or
treatment under study were reported in
19% of the studies of hypothermia for acute
ischemic stroke. All but one of these com-
plications concerned premature death, and
about 90% of these animals were excluded
from the analyses [20]. In another review of
several treatment strategies for acute ische-
mic stroke, only one of 45 studies men-
tioned predefined inclusion and exclusion
criteria, and in just 12 articles (27%)
exclusion of animals from analysis was
mentioned and substantiated. It is difficult
to believe that in every other study every
single experiment went as smoothly as the
investigators had planned [19].
Two factors limit the interpretation of
the above-mentioned data. First, the as-
sessment of possible confounders in system-
atic reviews was based on what was
reported in the articles, and may have been
incomplete because the authors considered
these aspects of study design not sufficiently
relevant to be mentioned. In addition,
definitions of randomisation, allocation
concealment, and blinding might vary
across studies, and, for example, randomly
picking animals from their cages may have
been called ‘‘randomisation.’’ Indeed, a
survey of a sample of authors of publica-
tions included in such reviews suggested
that this was sometimes the case [26].
Quality Checklists
At least four different but largely over-
lapping study-quality checklists have been
proposed for use in animal studies of
focal cerebral ischemia. These check-
lists have included items relating first to
the range of circumstances under which
efficacy has been shown and second to
the characteristics that might act as a
source of bias in individual experiments
[16].
Assessment of overall methodological
quality of individual studies with these
checklists is limited by controversy about
the composition of the checklists and,
more importantly, because the weight of
each of the individual components has
remained uncertain. For example, in the
most frequently used CAMARADES
checklist, ‘‘adequate allocation conceal-
ment’’ may have a much larger impact
on effect size than ‘‘compliance with
regulatory requirements’’ [16].
Does Methodological Quality
Matter?
Several systematic reviews and meta-
analyses have provided empirical evi-
dence that inadequate methodological
approaches in controlled clinical trials
are associated with bias. Clinical trials in
which authors did not report randomisa-
tion, adequately conceal treatment allo-
cation, or use double blinding yielded
larger estimates of treatment effects than
trials in which these study quality issues
were reported [12,27–32].
Table 2. Randomisation, blinded outcome assessment, and sample size calculation in systematic reviews of animal studies.
Disease Modeled
Year of
Publication
Number of
Publications
Randomisation,
n (%)
Blinded Outcome
Assessment, n (%)
A Priori Sample Size
Calculation, n (%)
Heart failure [24] 2003 9 6 (67) 9 (100) 0 (0)
Emergency medicine [33] 2003 290 94 (32) 31 (11) N/A
Ischemic stroke [19] 2005 45 19 (42) 18 (40) 0 (0)
Ischemic stroke [49] 2005 73 17 (23) 9 (12) N/A
Ischemic stroke [50] 2005 25 8 (32) 1 (4) N/A
Ischemic stroke [51] 2006 27 2 (7) 1 (4) N/A
Traumatic brain injury [2] 2007 17 2 (12) 3 (18) N/A
Hemorrhage in surgery [2] 2007 8 3 (38) 4 (50) N/A
Neonatal RDS [2] 2007 56 14 (25) 3 (5) N/A
Osteoporosis [2] 2007 16 5 (31) 0 (0) N/A
Ischemic stroke [16]a 2007 288 103 (36) 84 (29) 8 (3)
Parkinson’s disease [16] 2007 118 14 (12) 18 (15) 0 (0)
Multiple sclerosis [16] 2007 183 4 (2) 20 (11) 0 (0)
ALS [45] 2007 85 21 (25) 21 (25) 1 (1)
Brain injury [52] 2008 18 12 (67) 7 (39) N/A
Ischemic stroke [25] 2008 9 3 (33) 4 (44) 2 (22)
Ischemic stroke [53] 2009 19 1 (5) 5 (26) 0 (0)
aSummarises the data of six systematic reviews of treatment strategies for acute ischemic stroke. There is an overlap of 18 publications between references [16] and [19].
ALS, amyotrophic lateral sclerosis; N/A, data not available; RDS, respiratory distress syndrome.
doi:10.1371/journal.pmed.1000245.t002
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The impact of methodological quality
on the effect size in animal studies has
been examined less extensively. In animal
studies testing interventions in emergency
medicine, the odds of a positive result were
more than three times as large if the
publication did not report randomisation
or blinding as compared with publications
that did report these methods [33]. In
systematic reviews of FK-506 or hypother-
mia for acute ischemic stroke, an inverse
relation was found between effect size and
study quality, as assessed by a ten-item
study-quality checklist [20,34]. The same
review on hypothermia found large over-
statements of the reduction in infarct
volume in animal stroke studies without
randomisation or blinded outcome assess-
ment when they were compared with
randomised or blinded studies, but a
meta-analysis of 13 meta-analyses in ex-
perimental stroke describing outcomes in a
total of 15,635 animals found no statisti-
cally significant effect of these quality items
on effect size. In this meta-meta-analysis,
only allocation concealment was associat-
ed with a larger effect size [35].
A limitation of the meta-analyses assess-
ing the effect of study quality aspects on
effect size is the fact that no consideration
has been given to possible interactions
between quality items, and that only uni-
variate analyses were performed. Howev-
er, individual quality aspects that may
affect the results of meta-analyses of ani-
mal studies are unlikely to operate inde-
pendently. For example, nonrandomised
studies may be more likely than rando-
mised studies to disregard other quality
issues, such as allocation concealment or
blinding, or to use shorter delays for the
initiation of treatment, all of which may
affect study results. The relative impor-
tance of the various possible sources of bias
is therefore not yet known and is the
subject of ongoing research.
External Validity
Even if the design and conduct of an
animal study are sound and eliminate the
possibility of bias, the translation of its
results to the clinic may fail because of
disparities between the model and the
clinical trials testing the treatment strategy.
Common causes of such reduced external
validity are listed in Box 2 and are not
limited to differences between animals and
humans in the pathophysiology of disease,
but also include differences in comorbid-
ities, the use of co-medication, timing of
the administration and dosing of the study
treatment, and the selection of outcome
measures. Whereas the issues for internal
validity probably apply to the majority of
animal models regardless of the disease
under study, the external validity of a
model will largely be determined by
disease-specific factors.
Stroke Models
As mentioned above, the translation of
efficacy from animal studies to human
disease has perhaps been least successful
for neurological diseases in general and
for ischaemic stroke in particular. As there
is also no other animal model of disease
that has been more rigorously subjected
to systematic review and meta-analysis,
stroke serves as a good example of where
difficulties in translation might arise.
The incidence of stroke increases with
age, and stroke patients commonly have
other health problems that might increase
their stroke risk, complicate their clinical
course, and affect functional outcome. Of
patients with acute stroke, up to 75% and
68% have hypertension and hyperglycae-
mia, respectively [9,36]. While it is im-
portant to know whether candidate stroke
drugs retain efficacy in the face of these
comorbidities, only about 10% of focal
ischaemia studies have used animals with
hypertension, and fewer than 1% have
used animals with induced diabetes. In
addition, animals used in stroke models
were almost invariably young, and female
animals were highly underrepresented.
Over 95% of the studies were performed
in rats and mice, and animals that are
perhaps biologically closer to humans are
hardly ever used [16,19]. Moreover, most
animal studies have failed to acknowledge
the inevitable delay between the onset
of symptoms and the possibility to start
treatment in patients. In a systematic
review of animal studies of five different
neuroprotective agents that had also been
tested in 21 clinical trials including a total
of more than 12,000 patients with acute
ischaemic stroke, the median time be-
tween the onset of ischaemia and start of
treatment in the animal studies was just 10
minutes, which is infeasible in the clinic
[19]. In the large majority of clinical trials,
functional outcome is the primary mea-
sure of efficacy, whereas animal studies
usually rely on infarct volume. Several
studies have suggested that in patients
the relation between infarct volume and
functional outcome is moderate at best
[37,38]. Finally, the usual time of outcome
assessment of 1–3 days in animal models
contrasts sharply with that of 3 months in
patients [19]. For these reasons, it is not
surprising that, except for thrombolysis, all
treatment strategies proven effective in the
laboratory have failed in the clinic.
Other Acute Disease Models
Differences between animal models and
clinical trials similar to those mentioned
above have been proposed as causes of the
recurrent failure of a range of strategies to
reduce lethal reperfusion injury in patients
with acute myocardial infarction [6,7].
The failure to acknowledge the presence of
often severe comorbidities in patients, and
short and clinically unattainable onset-to-
treatment delays, have also limited the
external validity of animal models of
traumatic brain injury [2].
Chronic Disease Models
The external validity of models of
chronic and progressive diseases may also
be challenged by other factors. For the
treatment of Parkinson’s disease, research-
ers have mainly relied on injury-induced
models that mimic nigrostriatal dopamine
deficiency but do not recapitulate the slow,
progressive, and degenerative nature of
the disease in humans. Whereas in clinical
trials interventions were administered over
Box 2. Common Causes of Reduced External Validity of Animal
Studies
N The induction of the disease under study in animals that are young and
otherwise healthy, whereas in patients the disease mainly occurs in elderly
people with co-morbidities.
N Assessment of the effect of a treatment in a homogeneous group of animals
versus a heterogeneous group of patients.
N The use of either male or female animals only, whereas the disease occurs in
male and female patients alike.
N The use of models for inducing a disease or injury with insufficient similarity to
the human condition.
N Delays to start of treatment that are unrealistic in the clinic; the use of doses
that are toxic or not tolerated by patients.
N Differences in outcome measures and the timing of outcome assessment
between animal studies and clinical trials.
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a prolonged period of time in the context
of this slowly progressive disease, putative
neuroprotective agents were administered
before or at the same time as an acute
Parkinson’s disease-like lesion was induced
in the typical underlying animal studies
[39].
Based on the identification of single
point-mutations in the gene encoding
superoxide dismutase 1 (SOD1) in about
3% of the patients with amyotrophic
lateral sclerosis (ALS), mice carrying 23
copies of the human SOD1G93A trans-
gene are considered the standard model
for therapeutic studies of ALS. Apart from
the fact that this model may be valid only
for patients with SOD1 mutations, the
mice may suffer from a phenotype that is
so aggressive and so overdriven by its 23
copies of the transgene that no pharma-
cological intervention outside of the direct
inhibition of SOD1 will ever affect ALS-
related survival. In addition, it has been
suggested that these mice may be more
susceptible to infections and other non-
ALS related illnesses and that it is this
illness rather than the ALS that is alle-
viated by the experimental treatment.
Consistent with this hypothesis, several of
the compounds reported as efficacious in
SOD1G93A mice are broad-spectrum
antibiotics and general anti-inflammatory
agents [40].
Publication Bias
Decisions to assess the effect of novel
treatment strategies in clinical trials are,
ideally, based on an understanding of all
publicly reported information from pre-
clinical studies. Systematic review and
meta-analysis are techniques developed
for the analysis of data from clinical trials
and may be helpful in the selection of the
most promising strategies [16]. However,
if studies are published selectively on the
basis of their results, even a meta-analysis
based on a rigorous systematic review will
be misleading.
The presence of bias in the reporting of
clinical trials has been studied extensively.
There is strong empirical evidence that
clinical studies reporting positive or signif-
icant results are more likely to be pub-
lished, and that outcomes that are statis-
tically significant have higher odds of
being reported in full rather than as an
abstract. Such publication bias will lead to
overestimation of treatment effects and
can make the readily available evidence
unreliable for decision making [41].
Unfortunately, the presence of publica-
tion bias in animal studies has received
much less attention. In a recent systematic
review of studies testing the efficacy of
interventions in animal models of human
disease, only six reported testing for the
presence of publication bias, and such
bias was found in four [34,42–46]. No
study gave quantitative estimates of the
impact on effect size of publication bias
[47].
In a subsequent meta-analysis of 525
publications [47] included in systematic
reviews of 16 interventions tested in
animal studies of acute ischaemic stroke,
Egger regression and Trim and Fill
analysis suggested that publication bias
was widely prevalent. The analyses sug-
gested that publication bias might account
for around one-third of the efficacy re-
ported in systematic reviews of animal
stroke studies. Because this meta-analysis
included all reported experiments testing
an effect of an intervention on infarct size,
and not just the experiment with the
largest effect size from each publication,
at least some experiments testing ineffec-
tive doses (e.g., at the lower end of a dose-
response curve) were included. For this
reason, this meta-analysis is more likely to
underestimate than to overestimate the
effect of publication bias. It is therefore
probably more revealing that of the 525
publications, only ten (2%) did not report
at least one significant effect on either
infarct volume or neurobehavioural score
[47]. Although unproven, it appears
unlikely that the animal stroke literature
is uniquely susceptible to publication bias.
Nonpublication of the results of animal
studies is unethical not only because it
deprives researchers of the accurate data
they need to estimate the potential of
novel therapies in clinical trials, but also
because the included animals are wasted
because they do not contribute to accu-
mulating knowledge. In addition, research
syntheses that overstate biological effects
may lead to further unnecessary ani-
mal experiments testing poorly founded
hypotheses.
Practical Improvement
Strategies
Although there is no direct evidence of
a causal relationship, it is likely that the
recurrent failure of apparently promising
interventions to improve outcome in
clinical trials has in part been caused
by inadequate internal and external
validity of preclinical studies and publi-
cation bias favouring positive studies. On
the basis of ample empirical evidence
from clinical trials and some evidence
from preclinical studies, we suggest that
the testing of treatment strategies in
animal models of disease and its report-
ing should adopt standards similar to
those in the clinic to ensure that decision
making is based on high-quality and
unbiased data. Aspects of study quality
that should be reported in any manu-
script are listed in Box 3.
Not only should the disease or injury
itself reflect the condition in humans as
much as possible, but age, sex, and
comorbidities should also be modelled
where possible. The investigators should
Box 3. Aspects of Study Quality to Be Reported in the
Manuscript
N Sample size calculation: How the sample size was determined, and which
assumptions were made.
N Eligibility criteria: Inclusion and exclusion criteria for enrolment.
N Treatment allocation: The method by which animals were allocated to
experimental groups. If this allocation was by randomisation, the method of
randomisation.
N Allocation concealment: The method to implement the allocation sequence,
and if this sequence was concealed until assignment.
N Blinding: Whether the investigators and other persons involved were blinded
to the treatment allocation, and at which points in time during the study.
N Flow of animals: Flow of animals through each stage of the study, with a
specific attention to animals excluded from the analyses. Reasons for exclusion
from the analyses.
N Control of physiological variables: Whether and which physiological
parameters were monitored and controlled.
N Control of study conduct: Whether a third party controlled which parts of
the conduct of the study.
N Statistical methods: Which statistical methods were used for which analysis.
Recommendations based on [13,17].
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justify their selection of the model and
outcome measures. In turn, human clini-
cal trials should be designed to replicate, as
far as is possible, the circumstances under
which efficacy has been observed in
animals. For an adequate interpretation
of the potential and limitations of a novel
treatment strategy, a systematic review
and meta-analysis of all available evidence
from preclinical studies should be per-
formed before clinical trials are started.
Evidence of benefit from a single labora-
tory or obtained in a single model or
species is probably not sufficient.
Finally, the recognition of substantial
publication bias in the clinical literature
has led to the introduction of clinical trial
registration systems to ensure that those
summarising research findings are at
least aware of all relevant clinical trials
that have been performed [48]. Given
that a framework regulating animal ex-
perimentation already exists in many
countries, we suggest that this might be
exploited to allow the maintenance of
a central register of experiments per-
formed, and registration referenced in
publications.
Author Contributions
ICMJE criteria for authorship read and met:
HBvdW DWH ESS MJP SR VOMRM. Wrote
the first draft of the paper: HBvdW. Contrib-
uted to the writing of the paper: DWH ESS SR
VO MRM.
References
1. Hackam DG, Redelmeier DA (2006) Translation
of research evidence from animals to humans.
JAMA 296: 1731–1732.
2. Perel P, Roberts I, Sena E, Wheble P, Briscoe C,
et al. (2007) Comparison of treatment effects
between animal experiments and clinical trials:
systematic review. B M J 334: 197.
3. Hackam DG (2007) Translating animal research
into clinical benefit. B M J 334: 163–164.
4. Besselink MG, van Santvoort HC, Buskens E,
Boermeester MA, van Goor H, et al. (2008)
Probiotic prophylaxis in predicted severe acute
pancreatitis: a randomised, double-blind, place-
bo-controlled trial. Lancet 371: 651–659.
5. Shuaib A, Lees KR, Lyden P, Grotta J,
Davalos A, et al. (2007) NXY-059 for the
treatment of acute ischemic stroke. N Engl J Med
357: 562–571.
6. Dirksen MT, Laarman GJ, Simoons ML,
Duncker DJ (2007) Reperfusion injury in hu-
mans: a review of clinical trials on reperfusion
injury inhibitory strategies. Cardiovasc Res 74:
343–355.
7. Yellon DM, Hausenloy DJ (2007) Myocardial
reperfusion injury. N Engl J Med 357:
1121–1135.
8. O’Collins VE, Macleod MR, Donnan GA,
Horky LL, van der Worp BH, et al. (2006)
1,026 experimental treatments in acute stroke.
Ann Neurol 59: 467–477.
9. Van der Worp HB, Van Gijn J (2007) Clinical
practice. Acute ischemic stroke. N Engl J Med
357: 572–579.
10. Grotta J (2001) Neuroprotection is unlikely to be
effective in humans using current trial designs.
Stroke 33: 306–307.
11. Gladstone DJ, Black SE, Hakim AM, Heart and
Stroke Foundation of Ontario Centre of Excel-
lence in Stroke Recovery (2002) Toward wisdom
from failure. Lessons from neuroprotective stroke
trials and new therapeutic directions. Stroke 33:
2123–2136.
12. Juni P, Altman DG, Egger M (2001) Systematic
reviews in health care: Assessing the quality of
controlled clinical trials. B M J 323: 42–46.
13. Altman DG, Schulz KF, Moher D, Egger M,
Davidoff F, et al. (2001) The revised CONSORT
statement for reporting randomized trials: expla-
nation and elaboration. Ann Intern Med 134:
663–694.
14. Stroke Therapy Academic Industry Roundtable
(STAIR) (1999) Recommendations for standards
regarding preclinical neuroprotective and restor-
ative drug development. Stroke 30: 2752–2758.
15. Dirnagl U (2006) Bench to bedside: the quest for
quality in experimental stroke research. J Cereb
Blood Flow Metab 26: 1465–1478.
16. Sena E, Van der Worp HB, Howells D,
Macleod M (2007) How can we improve the
pre-clinical development of drugs for stroke?
Trends Neurosci 30: 433–439.
17. Macleod MR, Fisher M, O’Collins V, Sena ES,
Dirnagl U, et al. (2009) Good laboratory practice:
preventing introduction of bias at the bench.
Stroke 40: e50–e52.
18. Rosenthal R (1966) Experimenter effects in
behavioral research. New York: Appleton-Cen-
tury-Crofts.
19. Van der Worp HB, de Haan P, Morrema E,
Kalkman CJ (2005) Methodological quality of
animal studies on neuroprotection in focal
cerebral ischaemia. J Neurol 252: 1108–1114.
20. Van der Worp HB, Sena ES, Donnan GA,
Howells DW, Macleod MR (2007) Hypothermia
in animal models of acute ischaemic stroke: a
systematic review and meta-analysis. Brain 130:
3063–3074.
21. Campbell MJ, Julious SA, Altman DG (1995)
Estimating sample sizes for binary, ordered
categorical, and continuous outcomes in two
group comparisons. B M J 311: 1145–1148.
22. Festing MF, Altman DG (2002) Guidelines for the
design and statistical analysis of experiments using
laboratory animals. ILAR J 43: 244–258.
23. Bath PM, Macleod MR, Green AR (2009)
Emulating multicentre clinical stroke trials: a
new paradigm for studying novel interventions in
experimental models of stroke. Int J Stroke 4:
471–479.
24. Lee DS, Nguyen QT, Lapointe N, Austin PC,
Ohlsson A, et al. (2003) Meta-analysis of the
effects of endothelin receptor blockade on survival
in experimental heart failure. J Card Fail 9:
368–374.
25. Macleod MR, Van der Worp HB, Sena ES,
Howells DW, Dirnagl U, et al. (2008) Evidence
for the efficacy of NXY-059 in experimental focal
cerebral ischaemia is confounded by study
quality. Stroke 39: 2824–2829.
26. Samaranayake S (2009) Study Quality in Exper-
imental Stroke. Camarades Monograph Number
2, http://www.camarades.info/index_files/CM2.
pdf. (accessed 22/12/09).
27. Miettinen OS (1983) The need for randomisation
in the study of intended effects. Stat Med 2:
267–271.
28. Schulz KF, Chalmers I, Hayes RJ, Altman DG
(1995) Emperical evidence of bias. Dimensions of
methodological quality associated with estimates
of treatment effects in controlled trials. JAMA
273: 408–412.
29. Noseworthy JH, ebers GC, Vandervoort MK,
Farquhar RE, Yetisir E, et al. (1994) The impact
of blinding on the results of a randomized,
placebo-controlled multiple sclerosis clinical trial.
Neurology 44: 16–20.
30. Schulz KF, Grimes DA (2002) Blinding in
randomised trials: hiding who got what. Lancet
359: 696–700.
31. Schulz KF, Grimes DA (2002) Allocation con-
cealment in randomised trials: defending against
deciphering. Lancet 359: 614–618.
32. Schulz KF, Grimes DA (2005) Sample size
calculations in randomised trials: mandatory
and mystical. Lancet 365: 1348–1353.
33. Bebarta V, Luyten D, Heard K (2003) Emergen-
cy medicine animal research: Does use of
randomization and blinding affect the results?
Acad Emerg Med 10: 684–687.
34. Macleod MR, O’Collins T, Howells DW,
Donnan GA (2004) Pooling of animal experi-
mental data reveals influence of study design and
publication bias. Stroke 35: 1203–1208.
35. Crossley NA, Sena E, Goehler J, Horn J, van
der WB, et al. (2008) Empirical evidence of bias in
the design of experimental stroke studies: a
metaepidemiologic approach. Stroke 39:
929–934.
36. Van der Worp HB, Raaijmakers TW, Kappelle LJ
(2008) Early complications of ischemic stroke.
Curr Treat Options Neurol 10: 440–449.
37. Saver JL, Johnston KC, Homer D, Wityk R,
Koroshetz W, et al. (1999) Infarct volume as a
Five Key Papers in the Field
Hackam 2006 [1]: Shows that about a third of highly cited animal research
translates at the level of human randomised trials.
Sena 2007 [16]: Proposes minimum standards for the range and quality of pre-
clinical animal data before these are taken to clinical trials.
Dirksen 2007 [6]: Provides an overview of the various strategies that inhibit
reperfusion injury after myocardial infarction and discusses potential mechanisms
that may have contributed to the discrepancy between promising pre-clinical
data and the disappointing results in randomised clinical trials.
Scott 2008 [40]: Elaborate study suggesting that the majority of published
effects of treatments for amyotrophic lateral sclerosis are most likely measure-
ments of noise in the distribution of survival means as opposed to actual drug
effect.
Sena 2010 [47]: The first study to estimate the impact of publication bias on the
efficacy reported in systematic reviews of animal studies.
PLoS Medicine | www.plosmedicine.org 7 March 2010 | Volume 7 | Issue 3 | e1000245
surrogate or auxiliary outcome measure in
ischemic stroke clinical trials. Stroke 30: 293–298.
38. The National Institute of Neurological Disorders
and Stroke (NINDS) rt-PA Stroke Study Group
(2000) Effect of intravenous recombinant tissue
plasminogen activator on ischemic stroke lesion
size measured by computed tomography. Stroke
31: 2912–2919.
39. Kimmelman J, London AJ, Ravina B, Ramsay T,
Bernstein M, et al. (2009) Launching invasive,
first-in-human trials against Parkinson’s disease:
ethical considerations. Mov Disord 24: 1893–
1901.
40. Scott S, Kranz JE, Cole J, Lincecum JM,
Thompson K, et al. (2008) Design, power, and
interpretation of studies in the standard murine
model of ALS. Amyotroph Lateral Scler 9: 4–15.
41. Dwan K, Altman DG, Arnaiz JA, Bloom J,
Chan AW, et al. (2008) Systematic review of the
empirical evidence of study publication bias and
outcome reporting bias. PLoS One 3: e3081.
42. Dirx MJ, Zeegers MP, Dagnelie PC, van den
Bogaard T, van den Brandt PA (2003) Energy
restriction and the risk of spontaneous mammary
tumors in mice: a meta-analysis. Int J Cancer 106:
766–770.
43. Macleod MR, O’Collins T, Horky LL,
Howells DW, Donnan GA (2005) Systematic
review and metaanalysis of the efficacy of FK506
in experimental stroke. J Cereb Blood Flow
Metab 25: 713–721.
44. Juutilainen J, Kumlin T, Naarala J (2006) Do
extremely low frequency magnetic fields enhance
the effects of environmental carcinogens? A meta-
analysis of experimental studies. Int J Radiat Biol
82: 1–12.
45. Benatar M (2007) Lost in translation: treatment
trials in the SOD1 mouse and in human ALS.
Neurobiol Dis 26: 1–13.
46. Neitzke U, Harder T, Schellong K, Melchior K,
Ziska T, et al. (2008) Intrauterine growth
restriction in a rodent model and developmental
programming of the metabolic syndrome: a
critical appraisal of the experimental evidence.
Placenta 29: 246–254.
47. Sena ES, Van der Worp HB, Bath PMW,
Howells DW, Macleod MR (2010) Publication
bias in reports of animal stroke studies leads to
major overstatement of efficacy. PloS Biology.
PLoS Biol 8(3): e1000344. doi:10.1371/journal.
pbio.1000344.
48. De Angelis C, Drazen JM, Frizelle FA, Haug C,
Hoey J, et al. (2004) Clinical trial registration: a
statement from the International Committee of
Medical Journal Editors. N Engl J Med 351:
1250–1251.
49. Willmot M, Gibson C, Gray L, Murphy S, Bath P
(2005) Nitric oxide synthase inhibitors in exper-
imental ischemic stroke and their effects on infarct
size and cerebral blood flow: a systematic review.
Free Radic Biol Med 39: 412–425.
50. Willmot M, Gray L, Gibson C, Murphy S,
Bath PM (2005) A systematic review of nitric
oxide donors and L-arginine in experimental
stroke; effects on infarct size and cerebral blood
flow. Nitric Oxide 12: 141–149.
51. Gibson CL, Gray LJ, Murphy SP, Bath PM
(2006) Estrogens and experimental ischemic
stroke: a systematic review. J Cereb Blood Flow
Metab 26: 1103–1113.
52. Gibson CL, Gray LJ, Bath PM, Murphy SP
(2008) Progesterone for the treatment of experi-
mental brain injury; a systematic review. Brain
131: 318–328.
53. Banwell V, Sena ES, Macleod MR (2009)
Systematic review and stratified meta-analysis of
the efficacy of interleukin-1 receptor antagonist in
animal models of stroke. J Stroke Cerebrovasc
Dis 18: 269–276.
PLoS Medicine | www.plosmedicine.org 8 March 2010 | Volume 7 | Issue 3 | e1000245
